A novel AKT inhibitor, AZD5363, inhibits phosphorylation of AKT downstream molecules, and activates phosphorylation of mTOR and SMG-1 dependent on the liver cancer cell type
Open Access
- 14 January 2016
- journal article
- Published by Spandidos Publications in Oncology Letters
- Vol. 11 (3) , 1685-1692
Abstract
Due to frequent phosphoinositide 3‑kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway dysregulation, AKT is typically accepted as a promising anticancer therapeutic target. mTOR, in particular, represents a suitable therapeutic target for hepatocellular carcinoma, whilst suppressor with morphogenetic effect on genitalia family member‑1 (SMG‑1) is believed to serve a potential tumor suppressor role in human cancer. Despite SMG‑1 and mTOR belonging to the same PI3K‑related kinase family, the interactions between them are not yet fully understood. In the present study, a novel pyrrolopyrimidine‑derived compound, AZD5363, was observed to suppress proliferation in liver cancer Hep‑G2 and Huh‑7 cells by inhibiting the phosphorylation of downstream molecules in the AKT signal pathway, in a dose‑ and time‑dependent manner. AZD5363 activated the phosphorylation of mTOR, dependent on the liver cancer cell type, as it may have differing effects in various liver cancer cell lines. Additionally, AZD5363 also activated SMG‑1 within the same liver cancer cells types, which subsequently activated the phosphorylation of mTOR. In conclusion, the present study indicates that AZD5363 inhibited phosphorylation of AKT downstream molecules, and activated phosphorylation of mTOR and SMG‑1, dependent on the liver cancer type.Keywords
This publication has 41 references indexed in Scilit:
- Nonsense-mediated mRNA decay (NMD) in animal embryogenesis: to die or not to die, that is the questionCurrent Opinion in Genetics & Development, 2011
- Perifosine-induced inhibition of akt attenuates brain-derived neurotrophic factor/TrkB-induced chemoresistance in neuroblastoma in vivoCancer, 2011
- Increased Lipogenesis, Induced by AKT-mTORC1-RPS6 Signaling, Promotes Development of Human Hepatocellular CarcinomaGastroenterology, 2011
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and ActivityCancer Cell, 2011
- Smg1 is required for embryogenesis and regulates diverse genes via alternative splicing coupled to nonsense-mediated mRNA decayProceedings of the National Academy of Sciences, 2010
- Pivotal Role of mTOR Signaling in Hepatocellular CarcinomaGastroenterology, 2008
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008
- NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K MutationsCancer Research, 2008
- A Protective Role for the Human SMG-1 Kinase against Tumor Necrosis Factor-α-induced ApoptosisJournal of Biological Chemistry, 2008